Find A Clinical Trial

Disease Type: Colorectal

Trial ID C-800-25
Sponsor ID Agenus

“A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF BOTENSILIMAB (AGEN1181) AS MONOTHERAPY AND IN COMBINATION WITH BALSTILIMAB (AGEN2034) FOR THE TREATMENT OF ADVANCED, REFRACTORY MICROSATELLITE STABLE COLORECTAL CANCER WITHOUT LIVER METASTASES”

Principal Investigator
Chao Yin, MD
2 Locations
Trial ID 21386
Sponsor ID BNT122-01

“A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)”

1 Location
Trial ID NM1F-T1
Sponsor ID NM1F-T1-01

A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination With Pembrolizumab in Subjects With Locally Advanced/Metastatic Solid Tumors

Trial ID MRTX1133
Sponsor ID 1133-001

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Trial ID MRTX-0902 +/- Adagrasib
Sponsor ID 0902-001

A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients With Advanced Solid Tumors Harboring Mutations in the KRAS MAPK Pathway

Trial ID IMM-1-104
Sponsor ID IMM1104-101

A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Previously Treated RAS-Mutated Advanced or Metastatic Solid Tumors

Trial ID HFB-200603
Sponsor ID HFB-200603-01

A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200603 (Anti-BTLA Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors

Trial ID GCT1042
Sponsor ID GCT1042-01

A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors

Trial ID DK210 (EGFR)
Sponsor ID DEKA Biosciences

Dose-finding Phase 1 Trial: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Inoperable Locally Advanced and/or Metastatic EGFR+ Tumors With Progressive Disease Failing Systemic Therapy

Trial ID CBP-1019
Sponsor ID CBP-1019-101

An Open-Label, Non-randomized, Multinational, Multi-center Phase I/Ⅱ Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors